96401 is the CPT administration code for a subcutaneous or intramuscular injection of a non-hormonal anti-neoplastic agent — monoclonal antibodies, immunotherapies, and cytotoxic chemos given SC or IM. 96402 is the same route but for hormonal anti-neoplastic agents — LHRH/GnRH agonists (leuprolide, goserelin, triptorelin), GnRH antagonists (degarelix), and antiestrogens (fulvestrant). The route is identical; the drug class drives the code selection. Both codes are distinct from 96372, the generic SC/IM injection code, which is reserved for non-cancer drugs.
The chemotherapy SC/IM administration codes live in the AMA CPT manual under the Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration section (96401-96450). CMS adopts the CPT definitions and applies the same hierarchy and bundling rules described in Internet-Only Manual Publication 100-04 (Medicare Claims Processing Manual), Chapter 12, that govern the IV chemo administration family. The split between 96401 and 96402 was preserved through the 2026 CPT cycle and continues to follow the non-hormonal vs hormonal antineoplastic taxonomy.
The clinical relevance of the split has grown because the SC formulations of major IV immunotherapy products have launched: Keytruda Qlex (pembrolizumab + berahyaluronidase, J9277), Opdivo Qvantig (nivolumab + hyaluronidase-nvhy, J9289), Tecentriq Hybreza (atezolizumab + hyaluronidase-tqjs), Darzalex Faspro (daratumumab + hyaluronidase-fihj, J9144), and Phesgo (pertuzumab + trastuzumab + hyaluronidase-zzxf, J9316). All of these are non-hormonal antineoplastic SC products and code to 96401 on the administration line. Hormonal antineoplastic SC/IM agents remain the older depot oncology workhorses: Lupron Depot, Trelstar, Eligard, Zoladex, Firmagon, and Faslodex.
The most consequential coding error in this family is downcoding to 96372. The 96372 code carries a much lower administration RVU than 96401 or 96402, and using 96372 for a chemo or hormonal-chemo SC/IM injection both underpays the practice and triggers MAC LCD or NCCI flags on review.
In oncology practice, the 96401 code shows up most often on SC immunotherapy maintenance encounters: Keytruda Qlex every six weeks, Opdivo Qvantig every four weeks, Darzalex Faspro on the multiple-myeloma cycle calendar. The 96402 code dominates the urology and breast-cancer hormone-therapy schedule: Lupron Depot every one, three, four, or six months for prostate cancer, Faslodex monthly for HR-positive breast cancer, Firmagon loading-then-monthly for prostate cancer. The shared rule is that both 96401 and 96402 capture only the administration; the drug is reported separately on its own HCPCS J-code line, with units calculated per the J-code billing-unit convention and JW/JZ applied where the drug is supplied in a single-dose container.
The single largest source of denials in this family is using 96372 for a chemo SC/IM injection — downcoding under-pays the practice and triggers a flag if later audited. The second-largest pattern is using 96402 for non-cancer hormonal injections (e.g., testosterone, leuprolide given for fertility rather than prostate cancer). Read the diagnosis code on the claim and confirm it is an oncology indication before applying 96402.
The major commercial payers align with CMS on the 96401 vs 96402 vs 96372 split and on the one-line-per-drug convention. Variation appears at the prior-authorization layer for the underlying SC immunotherapy products (each PBM has its own infused-meds management program) rather than at the administration-code layer. Specialty-pharmacy fulfillment vs buy-and-bill choice also affects whether 96401/96402 appears on a medical claim at all.
| Payer | 96401 / 96402 rules | Notes |
|---|---|---|
| Medicare (Part B) | Aligns with CPT & Pub 100-04 Ch.12 | Source-of-truth payer for the non-hormonal vs hormonal split. MAC LCDs (Novitas, Palmetto, NGS, WPS, Noridian, FCSO) reiterate the AMA CPT definitions. Lupron Depot for non-cancer indications (precocious puberty, fertility) is not antineoplastic and codes to 96372, per AMA CPT examples and several MAC clarifications. |
| UnitedHealthcare | Aligns with CMS | UHC follows CPT for the SC/IM chemo code split. OptumRx infused-meds management drives PA approvals for SC immunotherapy launches (Keytruda Qlex, Opdivo Qvantig, Phesgo, Darzalex Faspro) — the administration code is fixed; the PA work concentrates on the drug. |
| Aetna (CVS Health) | Aligns with CMS | Aetna's CPB on oncology drug administration mirrors the CPT split. CVS Specialty fulfillment for several SC oncology products (Faslodex, Lupron Depot) routes through specialty pharmacy white-bag — the practice still bills 96401 or 96402 for the administration, with the drug acquired through SP. |
| Cigna / Express Scripts | Aligns with CMS | Cigna follows CPT. Accredo specialty pharmacy white-bag fulfillment is common for hormonal antineoplastics; the practice bills 96402 for the administration even when the drug was Accredo-supplied. Confirm PA approval before administration. |
| Humana | Aligns with CMS | MA-heavy book follows Medicare bundling and the chemo administration code split by default. CenterWell Specialty fulfills several oncology hormonal SC/IM products; administration codes are billed by the practice. |
| Denial pattern | What it means | Fix / appeal language |
|---|---|---|
| 96372 used for chemo SC/IM | An antineoplastic SC or IM injection was downcoded to 96372 (the generic non-chemo SC/IM injection). The line will pay but at a lower RVU and is a downcoding flag on audit. | Resubmit with 96401 (non-hormonal antineoplastic) or 96402 (hormonal antineoplastic) as appropriate. Appeal language: “Per AMA CPT 2026, SC/IM administration of an antineoplastic agent is reported with 96401 (non-hormonal) or 96402 (hormonal), not 96372. The drug administered (e.g., Phesgo, Faslodex, Lupron Depot for prostate cancer) is an antineoplastic. The corrected claim reflects the appropriate chemo SC/IM administration code.” |
| 96401 used for hormonal antineoplastic | A hormonal antineoplastic agent (leuprolide, fulvestrant, degarelix, goserelin, triptorelin) was coded as 96401 instead of 96402. | Resubmit with 96402. Appeal language: “The drug administered is a hormonal antineoplastic agent per AMA CPT classification. The corrected administration code is 96402 (chemotherapy SC/IM, hormonal anti-neoplastic), not 96401. The drug line and diagnosis code remain unchanged.” |
| 96402 used for non-cancer hormonal injection | A hormonal injection given for a non-cancer indication (testosterone replacement, hormone-replacement therapy, fertility leuprolide) was coded as 96402. 96402 is restricted to antineoplastic hormonal therapy. | Resubmit with 96372 and confirm the diagnosis code reflects the non-cancer indication. Appeal language: “The drug administered was given for a non-antineoplastic indication (diagnosis [code] reflects [condition]). 96402 applies only to hormonal anti-neoplastic administration; the correct code for a non-cancer hormonal SC/IM injection is 96372.” |
| Multiple 96401 lines for one combo product | A fixed-dose combination SC product (Phesgo, Keytruda Qlex, Opdivo Qvantig, Darzalex Faspro) was billed with one 96401 line per component drug instead of one line for the single administration event. | Consolidate to one 96401 line per encounter. Appeal language: “The product administered is a fixed-dose combination SC injection delivered as a single administration event. Per CPT, 96401 is reported once per administration event, not once per component. The corrected claim reports one 96401 line with the combination J-code on a single drug line.” |
| 96401 + 96413 same encounter without modifier 59/XU | A SC chemo administration (96401) and an IV chemo infusion (96413) were both billed on the same encounter without a distinct-procedural-service modifier, and the SC line denied as bundled. | Append modifier 59 (or the appropriate X-modifier subset, typically XU) to the 96401 line if documentation supports that the SC/IM was a clinically separate administration event. Appeal language: “The 96401 administration was a clinically distinct service from the 96413 infusion: separate drug (e.g., Faslodex SC vs IV chemo), separate clinical purpose, separate documentation of administration time and site. Modifier 59 (or XU) was added to indicate the distinct procedural service per NCCI Policy Manual Chapter 11.” |
Both codes describe a subcutaneous or intramuscular administration of an antineoplastic agent. The split is by drug class: 96401 is for non-hormonal anti-neoplastic agents (monoclonal antibodies, immunotherapies, cytotoxic chemos given SC/IM); 96402 is for hormonal anti-neoplastic agents (LHRH/GnRH agonists like leuprolide, antiestrogens like fulvestrant, GnRH antagonists like degarelix). The route is the same; the drug class drives the code.
No. 96372 is the generic therapeutic, prophylactic, or diagnostic SC/IM injection code for non-chemo drugs (e.g., vitamin B12, ceftriaxone, testosterone). When the drug being injected is an antineoplastic agent — cancer-treatment drug or hormonal cancer-treatment drug — CPT requires 96401 or 96402, not 96372. Using 96372 for a Faslodex or Lupron Depot injection is a common downcoding error and a NCCI flag.
No. 96402 is for hormonal antineoplastic agents — hormones used to treat cancer (typically prostate, breast, or endometrial cancer). Testosterone is a hormone replacement, not an antineoplastic, and is billed as a generic 96372 therapeutic SC/IM injection. Same logic for estrogen replacement, thyroid hormone, growth hormone — none are antineoplastic, so they belong to 96372.
Keytruda Qlex (pembrolizumab + berahyaluronidase alfa-pmph) is a non-hormonal antineoplastic given subcutaneously, so the administration code is 96401. The drug line is HCPCS J9277 with units calculated per the 1 mg billing unit. A typical Q6W maintenance encounter codes as 96401 × 1 + J9277 × 705 units (for the 705 mg fixed dose). The SC route administered over several minutes does not qualify as an infusion and does not trigger the 96413 family.
Phesgo (pertuzumab + trastuzumab + hyaluronidase-zzxf) is a non-hormonal antineoplastic SC fixed-dose combination, so the administration code is 96401. The drug line is HCPCS J9316 with units per the fixed-dose presentation (loading 1200/600 mg + 30,000 units hyaluronidase; maintenance 600/600 mg + 20,000 units hyaluronidase). One 96401 line per encounter regardless of the combo nature, because the SC fixed-dose injection is one administration event.
Faslodex is a selective estrogen-receptor degrader used as a hormonal antineoplastic in HR-positive breast cancer, given IM monthly. The administration code is 96402 (hormonal antineoplastic SC/IM). The drug line is HCPCS J9395 with units per the 25 mg billing unit (a 500 mg dose = 20 units of J9395). Standard practice gives two 250 mg syringes, one in each gluteal muscle — that is still one 96402 line per encounter; the dual-syringe administration is a single fulvestrant administration event for CPT purposes.
CPT instructions and most payer policies allow one 96401 (or 96402) per administered drug per encounter. If two separate non-hormonal antineoplastic agents are given SC at the same encounter, two 96401 lines may be appropriate — but check the specific payer policy, because some cap administration units and others apply NCCI bundling. A combination product administered through a single fixed-dose injection (e.g., Phesgo, Keytruda Qlex) is one administration event = one 96401 line, not one per component.
Yes. CMS hierarchy rules apply when an SC/IM antineoplastic administration shares an encounter with an IV chemo infusion. The IV chemo infusion (96413) outranks the SC/IM chemo (96401/96402) as the initial service. The SC/IM code remains separately billable as a same-day distinct service, but documentation should support that the SC/IM injection was a clinically separate administration event with its own drug and clinical purpose. Some payers will apply NCCI edits and may require modifier 59 / XU on the 96401 or 96402 line.
All sources are AMA CPT (commercially licensed), publicly available federal publications, FDA labeling, or paraphrased from trade-association educational materials. The methodology by which we resolve source disagreements is described in the Methodology.